BPC-157 Dosage: What Studies Actually Used — Not a Recommendation

Eleven thousand people search "bpc 157 dosage" every month, and the overwhelming majority of what answers that search hands back a specific number — a microgram amount, a daily schedule, sometimes a full chart scaled to body weight. This article does not do that, and the reason isn't caution for its own sake: there is no FDA-approved BPC-157 product, no approved label, and — unlike retatrutide, which at least has a real sponsor running human dosing trials — no completed human clinical trial of any kind that has established a safe or effective BPC-157 dose in people. What follows is not a gap in this article's research. It's the actual state of the published record, and reporting it accurately is the whole point.

What this article reports instead, precisely and every number traced to its source: what dose animal studies have actually administered to rodents, by route and by study, and what total milligram amount the three tiny human pilot studies covered in our BPC-157 evidence review actually gave their subjects. Neither of those is a human dosing recommendation, and this article says so again at every point where a reader might otherwise read one in.

What the animal studies actually used — and why the range itself is the finding

The single most useful fact in this section isn't any individual number. It's how wide the range is across the published animal literature, even before asking whether any of it applies to a human at all:

• •A 2004 rat gastric-ulcer study tested 200, 400, and 800 nanograms per kilogram, by intramuscular or intragastric injection, before or after inducing the ulcer¹.
• •A 2006 rat quadriceps-muscle-transection study tested three doses spanning three full orders of magnitude — 10 micrograms, 10 nanograms, or 10 picograms per kilogram — injected intraperitoneally once daily for the entire 72-day study².
• •A 2010 rat ligament-healing study used a different dose and unit for each of three separate administration routes: intraperitoneal injection at 10 micrograms or 10 nanograms per kilogram, a topical cream with 1.0 microgram dissolved per gram of cream applied at the injury site, and an oral route dosed through drinking water at 0.16 micrograms per milliliter, roughly 12 milliliters consumed per rat per day³.
• •A 2026 rat Achilles-tendon study — the most recent entry in this literature — used 10 micrograms per kilogram per day, injected intraperitoneally, for 4 weeks⁵.
• •A 2008 rat muscle crush-injury study tested intraperitoneal and topical-cream administration daily for 14 days — but its own published abstract does not state the specific microgram dose used, only the physical force delivered to cause the injury⁴. That's a real, stated gap in what this study's own published text discloses, not a number this article is willing to guess at.

Read across these five studies, the tested dose spans from picograms to micrograms per kilogram — a range covering roughly six orders of magnitude — depending on the specific tissue being studied, the injury model, the route of administration, and the individual lab running the experiment. That's not a design flaw in any one study; each dose was chosen for that specific experiment's own purposes. But it means the animal literature itself does not converge on a single validated dose even for rats, in a controlled research setting, before any question of species translation comes up at all. Rats also weigh roughly 300-400 grams in these studies — a fraction of an adult human's body weight — and were dosed almost entirely by intraperitoneal injection, a route directly into the abdominal cavity that bears no resemblance to a subcutaneous injection under the skin, the route most human use of BPC-157 actually involves. There is no validated formula this article, or any legitimate source, can use to convert a rat's intraperitoneal microgram-per-kilogram dose into a human subcutaneous one. Any chart claiming to do that math is performing an extrapolation the published science does not support.

What the human pilot studies actually gave their subjects

The three published human studies report a total milligram dose, not a weight-based one, and that's itself informative — none of them scaled the dose to the subject's body weight the way the animal studies (and a real clinical drug label) typically do:

• •The interstitial-cystitis pilot gave 12 women a single 10 mg intravesical injection during cystoscopy⁶.
• •The IV safety pilot gave 2 subjects an escalating dose: 10 mg on day one, then 20 mg on day two, each infused over one hour⁷.
• •The knee-pain study's own published methods and results do not state the specific milligram dose used for the intra-articular injections it retrospectively reviewed⁸ — reported here as exactly that: information the published paper doesn't disclose, not a number this article is willing to infer from context.

That's the complete published human dosing record for BPC-157: two total-milligram numbers from two tiny pilot studies, and one study that doesn't report its own dose at all. None of the three used a controlled, placebo-compared, dose-ranging design of the kind that establishes a real dose-response relationship — the exact design retatrutide's own Phase 2 trials used, and which our retatrutide dosing article covers as an example of what that process actually looks like when it happens.

Why there is no "BPC-157 dosing chart" on this page

Searches for a BPC-157 dosing chart are common enough that this article addresses the request directly rather than ignoring it: what you're looking for — a table converting body weight into a daily or per-injection microgram amount for ongoing use — does not exist as a validated, study-derived figure anywhere in the published literature this article traced. Building one would require exactly the extrapolation the section above explains isn't supportable: picking one of several wildly different animal doses, converting it across species by a method no controlled human trial has validated, and applying it to a route (ongoing subcutaneous self-injection) none of the three human pilot studies even tested. Numbers circulating on vendor sites and forums that describe a "typical" range are not sourced to any peer-reviewed study this review could locate; this article is not repeating them, because doing so would misrepresent unvalidated figures as documented ones.

What this section offers instead is the same honest substitute our retatrutide dosing article offers for a structurally similar problem: a plain table of what's actually been documented, consolidated from the sections above, clearly labeled as study data rather than guidance. If you already have an actual dose figure from somewhere else, our BPC-157 reconstitution calculator will do the vial-to-syringe arithmetic on it — pure math on whatever number you enter, with no claim that the number itself is validated, appropriate, or legal, because — as our evidence review and our side-effects article both cover — there currently is no FDA-set dosing standard to check it against.

The bottom line

Across five animal studies and three human pilot studies, the honest summary is short: animal research has tested doses spanning roughly six orders of magnitude depending on tissue, route, and lab, with no single dose emerging as standard even within that literature; the human pilot studies report total milligram amounts, not weight-based doses, from two of three published studies, with the third disclosing no dose at all; and no controlled human trial — the kind that actually establishes a safe, effective dose the way retatrutide's ongoing Phase 2/3 program or tirzepatide's completed FDA review did — has ever been run. There is no BPC-157 dosing schedule this site, or any other legitimate source, can responsibly hand you. What's documented above is what the published research actually administered, in the specific study that administered it, under research or clinical supervision that a reader outside that study cannot replicate. For the safety data those same studies (and others) reported, see our side-effects article; for the full evidence picture, including the regulatory status behind why no approved dose exists, see our evidence review.